Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed uveal melanoma

- Metastatic disease

- Measurable disease, defined as ≥ 1 measurable lesion as measured by RECIST criteria

- No curative surgical treatment envisaged

- No active brain metastases (if clinical suspicion, must have a brain CT scan within
28 days)

PATIENT CHARACTERISTICS:

- WHO performance status (PS) 0-1 OR Karnofsky PS 70-100%

- Life expectancy ≥ 12 weeks

- Hemoglobin ≥ 10 g/dL

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR calculated creatinine
clearance ≥ 50 mL/min

- Proteinuria < 2+ on urinary dipstick OR 24-hour proteinuria ≤ 1 g

- Total bilirubin ≤ 1.5 times ULN

- AST/ALT ≤ 2.5 times ULN

- Lactate dehydrogenase ≤ 5 times ULN

- INR and PT ≤ 1.5 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 6 months after
completion of study treatment

- No uncontrolled active disease or at risk of bleeding, ongoing infection, or clotting
disorder

- No other cancer except for skin carcinomas and cervical carcinoma in situ

- No pre-existing peripheral neuropathy, > grade 2 (NCI CTC-AE)

- No failure to comply with the medical follow-up of the study for geographical,
social, or psychological reasons

- No recent thrombophlebitis or pulmonary embolism within the past 6 months

- No uncontrolled hypertension (systolic BP > 150 mm Hg and/or diastolic BP > 100 mm
Hg)

- No concurrent active cardiovascular disease, uncontrolled by medical treatment within
the past 6 months, including any of the following:

- Unstable angina

- Severe hypertension

- Severe arrhythmia

- No unhealed wound, active peptic ulcer, bone fracture, history of abdominal fistula,
gastrointestinal perforation, or intra-abdominal abscess within the past 6 months

- No known hypersensitivity to bevacizumab, temozolomide, or their excipients

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy for metastatic disease

- At least 24 hours since insertion of central infusion port

- More than 5 days since prior non-hepatic biopsy or aspiration cytology

- More than 10 days since prior aspirin (> 325 mg/day), clopidogrel (> 75 mg/day), or
full-dose oral or parenteral anticoagulant therapy, except prophylactic anticoagulant
therapy prior to inclusion in the study

- More than 14 days since prior laparoscopic liver biopsy

- More than 28 days since prior major surgery

- More than 28 days since prior participation in another study with experimental
treatment

- No other concurrent anticancer treatment